Hutchinson–Gilford progeria syndrome is an exceptionally rare disorder that accelerates aging, typically shortening life to the teenage years. Its most common cause is a point mutation in the LMNA gene, which produces progerin, a permanently farnesylated form of lamin A that accumulates at the nuclear envelope. By disrupting nuclear architecture, progerin triggers dysfunction across multiple tissues. Heart disease is a major source of mortality, but it has remained unclear how much of this damage originates directly within cardiomyocytes rather than arising indirectly from stiffened blood vessels. A new mouse study identifies a loss of cardiac RNA methylation as a key link between nuclear-envelope damage and the inflammation, fibrosis and functional decline characteristic of progeria.
The researchers began with an inducible mouse model in which tamoxifen activates Cre recombinase to express progerin specifically in cardiomyocytes. Progerin accumulated at the nuclear envelope of heart cells but was not detected in skeletal muscle or lung, establishing a system for testing whether cardiomyocytes can autonomously develop disease-like changes. Within months, the engineered hearts developed collagen deposition, increased expression of the fibrosis genes Col1a1 and Col3a1, and molecular signs of hypertrophy and heart failure. Expression of the hypertrophic marker Myh7 rose before cardiomyocytes became measurably larger, while the heart-failure marker Nppb and inflammatory genes Ifna and Ifnb also increased.
Expression of genes involved in calcium handling declined alongside these abnormalities. The affected genes included Casq1, Casq2 and Stim1, whose products help coordinate calcium storage, release and contraction in muscle cells. Echocardiography showed reduced stroke volume and cardiac output, although ejection fraction was preserved, indicating that the heart could maintain its shape and contractility while pumping less blood effectively. The induced mice also had a shorter median lifespan than littermate controls. These findings showed that sustained progerin production in cardiomyocytes is sufficient to initiate myocardial fibrosis, pathological remodeling and premature death.
The investigators then searched for a molecular mechanism connecting lamin A dysfunction to cardiac deterioration. They focused on N6-methyladenosine, or m6A, an internal modification on messenger RNA that helps regulate transcript stability and gene expression. The m6A “writer” complex consists of METTL3, the catalytic enzyme, and METTL14, its structural partner. Both proteins were reduced in the progerin-expressing hearts, along with the overall abundance of m6A-modified RNA. The same decline appeared in two independent systemic progeria models: LmnaG609G/G609G mice, which accumulate progerin, and Zmpste24-deficient mice, which accumulate prelamin A. Naturally aged mouse hearts also showed lower METTL3 and METTL14 levels, while kidneys did not, indicating that suppression of the methylation machinery is a feature of cardiac aging rather than a universal effect throughout the body.
Cell experiments suggested that loss of the m6A writers was not merely a marker of damaged tissue. Reducing either METTL3 or METTL14 in isolated neonatal cardiomyocytes increased the senescence markers p21 and p16 and stimulated inflammatory genes including Ifna, Ifnb and Il6. Simultaneous depletion produced the strongest response. RNA-decay experiments offered a more detailed explanation: after METTL14 was reduced, the inflammatory transcripts Ifna and Ifnb persisted longer than normal. Their loss of m6A therefore appeared to slow degradation, allowing inflammation-promoting messages to accumulate. In progeroid hearts, methylated-RNA immunoprecipitation confirmed that Ifna and Ifnb carried less m6A than the same transcripts in healthy control tissue.
Calcium regulation was affected in the opposite manner, revealing that m6A does not act through a single uniform mechanism. METTL3 and METTL14 depletion reduced the abundance of calcium-handling transcripts, particularly Casq1 and Casq2. Progeroid hearts showed reduced m6A enrichment and METTL14 binding on both messages. When METTL14 was silenced, however, Casq2 messenger RNA decayed more rapidly, whereas Casq1 stability changed little, indicating that Casq1 abundance is probably controlled by additional pathways. Live-cell imaging revealed the physiological consequence: cardiomyocytes with reduced METTL14 generated smaller spontaneous calcium transients, a sign of disturbed calcium cycling. Directly lowering Casq2, but not Casq1, induced senescence markers and increased the fibrotic gene Col3a1.
The therapeutic experiments asked whether restoring METTL14 could interrupt this damaging cascade. Researchers delivered METTL14 to two-month-old mice with an adeno-associated virus type 9 vector controlled by the cardiac troponin T promoter, directing expression primarily to the myocardium. In the cardiomyocyte-specific progeria model, the treatment increased METTL14 and also raised endogenous METTL3, consistent with the two proteins stabilizing one another. It restored Casq1 and Casq2 expression, suppressed Ifna and Ifnb, and reduced the fibrosis markers Col1a1 and Col3a1. Histological staining confirmed that myocardial collagen accumulation was substantially lower than in animals receiving a control green fluorescent protein vector.
Similar protection appeared in Zmpste24-deficient mice, a model of systemic premature aging. Cardiac METTL14 expression restored Casq2, reduced Ifnb and suppressed genes associated with fibrosis and heart failure, including Col1a1, Col3a1, Nppa and Nppb. The senescence markers Cdkn1a and Cdkn2a did not change, suggesting that the intervention primarily modified ongoing tissue injury rather than erasing every molecular sign of cellular aging. Treated animals also performed better on the rotarod test, which measures motor coordination and endurance, and their median lifespan was significantly longer than that of control animals. The benefit therefore extended beyond molecular markers and histological improvement to organism-level outcomes.
The results establish a cardiac epitranscriptomic axis linking lamin A, m6A methylation and cardiomyocyte homeostasis. Progerin disrupts the nuclear lamina, METTL3 and METTL14 decline, and the resulting loss of RNA modification destabilizes calcium-handling transcripts while allowing inflammatory transcripts to persist. The combined effects promote senescence-like signaling, impaired calcium cycling, fibrosis and declining cardiac performance. Restoring METTL14 largely reverses this sequence in two progeria models, providing a possible therapeutic target for cardiovascular complications in Hutchinson–Gilford progeria syndrome. The study does not yet establish a treatment for people, and it leaves important questions about optimal delivery, timing and whether established damage can be reversed rather than merely prevented.
Subject of Research: Cardiac RNA methylation as a mechanism and therapeutic target in progeria-associated cardiomyopathy.
Article Title: METTL14‐Mediated m6A Methylation Preserves Cardiomyocyte Homeostasis and Attenuates Progeria‐Associated Cardiac Remodeling
Article References: Wang, S., Zhang, J., Ao, Y., Rao, D., Yu, C., Xu, C., Wang, M., Li, M., Huang, X., Zhang, J., Mei, R., Zhang, Z., Sun, J., Duan, J., Sun, Y., Wang, Z., Su, W., & Liu, B. (2026). METTL14 ‐Mediated m 6 A Methylation Preserves Cardiomyocyte Homeostasis and Attenuates Progeria‐Associated Cardiac Remodeling. Aging Cell, 25(10), Article e70765. https://doi.org/10.1111/acel.70765
Image Credits: AI Generated
DOI: 10.1111/acel.70765
Keywords: progeria, cardiac aging, METTL14, RNA methylation, cardiomyocytes, cardiac fibrosis, progerin, calcium handling, gene therapy, m6A, Mediated, Methylation
News Source: Juliet Wilcox. (October 19, 2026). RNA Methylation Restores Heart Function in Progeria Mice. Scienmag.
